Ffisayil 2 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

EFFISAYIL™ 2 met its primary and key secondary endpoint, demonstrating that spesolimab, an anti-interleukin-36 receptor antibody, can prevent flares in adolescents and adults with generalized pustular psoriasis (GPP) up to 48 weeks.1,2

Rheinland pfalzLaura lessenichCarinne brouillonEuropean unionCorporate communicationsBoehringer ingelheimManaging directorsHuman pharmaMainland chinaMedia contactFfisayil 2Generalized pustular psoriasisClinical trialsCarinne brouillonHuman pharmaRare skin disease